Display options
Cite
Strittmatter F, Madersbacher S, Stief CG, et al. Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Urologe A. 2012;51(8):1125-36doi: 10.1007/s00120-012-2943-1.
Strittmatter, F., Madersbacher, S., Stief, C. G., & Gratzke, C. (2012). Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Der Urologe. Ausg. A, 51(8), 1125-36. https://doi.org/10.1007/s00120-012-2943-1
Strittmatter, F, et al. "Medikamentöse Therapie des benignen Prostatasyndroms." [Medical therapy of lower urinary tract symptoms [corrected]]. Der Urologe. Ausg. A vol. 51,8 (2012): 1125-36. doi: https://doi.org/10.1007/s00120-012-2943-1
Strittmatter F, Madersbacher S, Stief CG, Gratzke C. Medikamentöse Therapie des benignen Prostatasyndroms. [Medical therapy of lower urinary tract symptoms [corrected]]. Urologe A. 2012 Aug;51(8):1125-36. doi: 10.1007/s00120-012-2943-1. German. PMID: 22782192.
Copy Download .nbib Format: NLM
Share it on

Urologe A. 2012 Aug;51(8):1125-36. doi: 10.1007/s00120-012-2943-1.

[Medical therapy of lower urinary tract symptoms [corrected]].

Der Urologe. Ausg. A

[Article in German]
F Strittmatter, S Madersbacher, C G Stief, C Gratzke

Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum der Universität München-Großhadern , Marchioninistr. 15, 81377 München, Deutschland. [email protected]

PMID: 22782192 DOI: 10.1007/s00120-012-2943-1

Abstract

Male lower urinary tract symptoms (LUTS) include storage and voiding disorders and should be carefully evaluated before the start of any treatment. Medical therapy is directed at improving symptoms and reducing the risk of progression in order to improve quality of life and prevent complications, such as acute urinary retention, or the need for surgical intervention. Careful assessment of the individual complaints helps to identify the best drug which should be adapted to each individual patient's risk profile. At present, α(1)-adrenoreceptor inhibitors and 5-alpha reductase inhibitors and their combination form the gold standard for pharmacological treatment. In addition, anticholinergic agents are increasingly being used as monotherapy or in combination with α1-adrenocepetor inhibitors for patients with predominant storage disorders while phosphodiesterase 5 (PDE5) inhibitors may be suitable for patients suffering from LUTS and concomitant erectile dysfunction.

References

  1. Urology. 2005 Oct;66(4):780-8 - PubMed
  2. J Urol. 2004 Oct;172(4 Pt 1):1399-403 - PubMed
  3. BJU Int. 2005 Jun;95 Suppl 4:19-28 - PubMed
  4. J Urol. 2005 Dec;174(6):2273-5. discussion 2275-6 - PubMed
  5. Eur Urol. 2007 Jun;51(6):1717-23 - PubMed
  6. Nat Clin Pract Urol. 2007 Jul;4(7):368-78 - PubMed
  7. N Engl J Med. 1996 Aug 22;335(8):533-9 - PubMed
  8. Cochrane Database Syst Rev. 2000;(2):CD001042 - PubMed
  9. BJU Int. 2011 Aug;108(3):388-94 - PubMed
  10. J Auton Pharmacol. 2001 Oct-Dec;21(5-6):243-8 - PubMed
  11. Urology. 2004 Dec;64(6):1081-8 - PubMed
  12. Eur Urol. 2000 Mar;37(3):306-13 - PubMed
  13. J Sex Med. 2008 Sep;5(9):2170-8 - PubMed
  14. Urology. 2003 Jan;61(1):119-26 - PubMed
  15. BJU Int. 2005 Sep;96(4):572-7 - PubMed
  16. Br J Pharmacol. 2006 Feb;147 Suppl 2:S88-119 - PubMed
  17. Urology. 2008 Nov;72(5):1061-7; discussion 1067 - PubMed
  18. Urologe A. 1997 Jul;36(4):327-33 - PubMed
  19. Prostate Cancer Prostatic Dis. 1998 Dec;1(6):332-335 - PubMed
  20. Cochrane Database Syst Rev. 2000;(2):CD001043 - PubMed
  21. Urologe A. 2009 Dec;48(12):1503-16 - PubMed
  22. Drugs. 2006;66(3):287-301 - PubMed
  23. Eur Urol. 2006 Apr;49(4):651-8 - PubMed
  24. J Urol. 2000 Aug;164(2):578-83 - PubMed
  25. Clin Ther. 2007 Jan;29(1):17-25 - PubMed
  26. J Urol. 2003 Jun;169(6):2253-6 - PubMed
  27. Eur Urol. 2004 Nov;46(5):547-54 - PubMed
  28. Neurourol Urodyn. 2008;27(3):226-30 - PubMed
  29. J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004 - PubMed
  30. World J Urol. 2008 Dec;26(6):603-9 - PubMed
  31. Eur Urol. 2007 Jul;52(1):221-9 - PubMed
  32. Urologe A. 2008 Feb;47(2):141-8 - PubMed
  33. J Cataract Refract Surg. 2005 Apr;31(4):664-73 - PubMed
  34. World J Urol. 2010 Feb;28(1):17-22 - PubMed
  35. Urology. 2010 May;75(5):1149-55 - PubMed
  36. N Engl J Med. 2010 Apr 1;362(13):1192-202 - PubMed
  37. Eur Urol. 2006 Apr;49(4):740-5 - PubMed
  38. J Sex Med. 2009 Feb;6(2):544-52 - PubMed
  39. JAMA. 2006 Nov 15;296(19):2319-28 - PubMed
  40. N Engl J Med. 2003 Dec 18;349(25):2387-98 - PubMed
  41. Eur Urol. 2012 May;61(5):917-25 - PubMed
  42. JAMA. 2011 Sep 28;306(12):1344-51 - PubMed
  43. BJU Int. 2008 Mar;101 Suppl 3:17-21 - PubMed
  44. Eur Urol. 2010 Jan;57(1):123-31 - PubMed
  45. Urology. 2003 Jul;62(1):1-9 - PubMed
  46. Am Fam Physician. 2008 May 15;77(10):1403-10 - PubMed
  47. Cochrane Database Syst Rev. 2003;(1):CD002081 - PubMed
  48. Can Urol Assoc J. 2008 Feb;2(1):16-21 - PubMed
  49. N Engl J Med. 2003 Jul 17;349(3):215-24 - PubMed
  50. World J Urol. 2007 Dec;25(6):627-33 - PubMed
  51. Int J Clin Pract. 2008 Oct;62(10):1547-59 - PubMed
  52. Eur Urol. 2012 May;61(5):994-1003 - PubMed
  53. Cochrane Database Syst Rev. 2002;(4):CD003851 - PubMed

MeSH terms

Publication Types